Impact of taxanes in association with anthracyclines in 1st line chemotherapy for metastatic breast cancer (MBC):: Comprehensive review of 2805 patients in 7 phase III trials.

被引：0
|
作者：
Bria, E [1 ]
Nistico, C [1 ]
Cuppone, F [1 ]
Giannarelli, D [1 ]
Terzoli, E [1 ]
机构：
[1] Regina Elena Inst Canc Res, Rome, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
659
引用
收藏
页码：41S / 41S
页数：1
相关论文
共 50 条
  • [21] A review of clinical endpoints and use of quality of life outcomes in phase III metastatic breast cancer clinical trials.
    Tatla, Raman
    Landaverde, Denis
    Victor, Charles
    Miles, David
    Verma, Sunil
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [22] Phase III study on efficacy of taxanes plus bevacizumab with or without capecitabine as first-line chemotherapy in metastatic breast cancer
    Lueck, Hans-Joachim
    Luebbe, Kristina
    Reinisch, Mattea
    Maass, Nicolai
    Feisel-Schwickardi, Gabriele
    Tome, Oliver
    Janni, Wolfgang
    Aydogdu, Mustafa
    Neunhoeffer, Tanja
    Ober, Angelika
    Aktas, Bahriye
    Park-Simon, Tjoung-Won
    Schumacher, Claudia
    Hoeffkes, Heinz-Gert
    Illmer, Thomas
    Wagner, Harald
    Mehta, Keyur
    von Minckwitz, Gunter
    Nekljudova, Valentina
    Loibl, Sibylle
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2015, 149 (01) : 141 - 149
  • [23] Phase III study on efficacy of taxanes plus bevacizumab with or without capecitabine as first-line chemotherapy in metastatic breast cancer
    Hans-Joachim Lück
    Kristina Lübbe
    Mattea Reinisch
    Nicolai Maass
    Gabriele Feisel-Schwickardi
    Oliver Tomé
    Wolfgang Janni
    Mustafa Aydogdu
    Tanja Neunhöffer
    Angelika Ober
    Bahriye Aktas
    Tjoung-Won Park-Simon
    Claudia Schumacher
    Heinz-Gert Höffkes
    Thomas Illmer
    Harald Wagner
    Keyur Mehta
    Gunter von Minckwitz
    Valentina Nekljudova
    Sibylle Loibl
    [J]. Breast Cancer Research and Treatment, 2015, 149 : 141 - 149
  • [24] A phase III, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: Subgroup analyses
    Kaufman, Peter Andrew
    Cortes, Javier
    Awada, Ahmad
    Yelle, Louise
    Perez, Edith A.
    Wanders, Jantien
    Olivo, Martin S.
    He, Yi
    Dutcus, Corina
    Twelves, Christopher
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [25] Oral Vinorelbine in Combination With Capecitabine as a First Line Treatment in Patients (pts) With Metastatic Breast Cancer (MBC) Previously Treated With Anthracyclines ± Taxanes - Preliminary Results of a Multicentric Phase II Trial in Egypt
    Kandil, A.
    Hamada, E.
    Moawad, M.
    El Arab, L. Ezz
    Metwalli, H.
    Bathiouny, M.
    Mourad, C.
    [J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 : S351 - S351
  • [26] How long have I got? Estimating survival for women starting first-line chemotherapy for metastatic breast cancer (MBC): A systematic review of recent randomized trials.
    Kiely, B. E.
    Soon, Y.
    Tattersall, M. H.
    Stockler, M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [27] Phase I study of vinorelbine (VRL) alternating i.v. and oral in combination with docetaxel (DTX) as 1st line chemotherapy (CT) of metastatic breast cancer (MBC).
    Koralewski, P
    Morawiec, MB
    Tekiela, A
    Chmielowska, E
    Campone, M
    Bonneterre, J
    Longerey, B
    de Micheaux, SL
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 48S - 48S
  • [28] Preliminary data of a phase II randomized trial of taxotere (TXT) and doxorubicin (DOX) given simultaneously or sequentially as 1st line chemotherapy (CT) for metastatic breast cancer (MBC)
    Koroleva, I
    Wojtukiewicz, M
    Zaluski, J
    Korytova, L
    Biakhov, M
    Gadel-Mawia, N
    Gouda, Y
    Krishtopin, V
    Dubois, C
    Blanc, C
    [J]. EUROPEAN JOURNAL OF CANCER, 1999, 35 : S317 - S317
  • [29] Phase II study of vinorelbine (VRL) alternating i.v. and oral in combination with docetaxel (DTX) as 1st line chemotherapy (CT) of metastatic breast cancer (MBC).
    Moriawiec, MB
    Ulanska, M
    Quispe, OZ
    Koralewski, P
    Tekiela, A
    Chmielowska, E
    Longerey, B
    de Micheaux, SL
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 73S - 73S
  • [30] META-ANALYSIS OF PATIENTS (PTS) PREVIOUSLY TREATED WITH TAXANES FROM THREE RANDOMIZED TRIALS OF BEVACIZUMAB (BV) AND FIRST-LINE CHEMOTHERAPY AS TREATMENT FOR METASTATIC BREAST CANCER (MBC)
    Miles, D. W.
    Romieu, G.
    Dieras, V.
    Chen, D.
    Duenne, A.
    O'Shaughnessy, J.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : 97 - 97
12345